Sava Technologies Achieves 10-Day Continuous Glucose Monitoring Milestone with Next-Generation Microsensor Platform
Key Insights
Sava Technologies (search) raised $19 million in Series A funding led by Balderton Capital (search) and Pentland Ventures (search) to advance its multi-molecule biosensor platform for real-time biomarker detection.
Clinical trial results from 50 diabetes (search) patients showed Sava's proprietary microsensor technology delivered accurate glucose readings for up to 10 days of continuous wear, a world-first achievement for microsensor platforms.
The pain-free, cost-effective continuous glucose monitor aims to expand CGM adoption beyond the current 1% of diabetes (search) patients who use these devices, targeting the $11 billion annual CGM market.
Sava Technologies (search) has raised $19 million in Series A funding to accelerate development of its breakthrough multi-molecule biosensor platform, following clinical trial results that demonstrated world-first performance in continuous glucose monitoring. The round was led by Balderton Capital (search) and Pentland Ventures (search), with participation from new investors Norrsken VC (search) and JamJar Investments (search), alongside existing backers including True, Italian Founders Fund, and Athletico Ventures.
Clinical Breakthrough in Microsensor Technology
The London-based company's latest clinical trial, conducted independently across sites in Oxford and Cambridge, enrolled 50 patients with Type 1 and insulin-dependent Type 2 diabetes (search). Early results from the first 25 patients revealed that Sava's proprietary technology delivered reliable, accurate glucose readings for up to 10 days of continuous wear—a milestone no other microsensor platform has achieved to date.
"Most microsensor systems fail to last 5 days, and many struggle beyond 24 hours," the company noted. The trial was designed in collaboration with leading diabetes (search) clinicians and regulators, providing a critical foundation for future regulatory submissions and Sava's pivotal study set to launch in the coming year.
"This clinical trial marks a pivotal moment not just for Sava, but for the future of biosensing and personalised healthcare," said Rafaël Michali, Co-Founder and co-CEO of Sava. "The data generated so far has shown that our technology has the potential to match the performance of leading CGMs in the market today, without the invasiveness or high cost of filament-based systems."
Addressing Market Access Barriers
Currently, only 1% of people with diabetes (search) use continuous glucose monitors, despite the technology generating over $11 billion in annual sales with 10% year-on-year growth. Existing devices are often painful, expensive, and inaccessible, creating significant barriers to adoption.
Sava's device promises to transform diabetes (search) care by offering a pain-free, cost-effective alternative that could dramatically expand CGM accessibility. "Understanding what's going on in our bodies is the first step to improving our health," said James Wise, Partner at Balderton. "Sava's innovation has the potential to democratise access to glucose monitoring, as well as many other biomarkers, making them more practical for the millions of people who need them but can't afford or tolerate the current options."
Multi-Biomarker Platform Strategy
Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, Sava has developed a modular, multi-analyte sensing platform capable of detecting biomarkers just beneath the skin in real-time. While glucose monitoring represents the first commercial application, the platform is designed to track multiple molecules simultaneously.
"Glucose is only the beginning," said Renato Circi, Co-Founder and co-CEO. "We have built a modular platform, capable of multi-molecule sensing. New molecules will create new use cases. What we're building here is not just a device, but a whole new technological foundation for personalised healthcare, where anyone can use a biosensor to understand their health in real-time, at a molecular level."
Commercial Expansion Plans
The latest funding brings Sava's total raised capital to $32 million, with backing from leading venture capital firms, returning angel investors, and funding from the EU and UK Government. The company has rapidly expanded to over 60 employees, including experts behind market-leading CGMs.
The new capital will support further expansion of Sava's team, advance automated manufacturing capabilities to reach target launch volumes, and accelerate clinical validation of its microsensor technology. With growing interest among athletes and health-conscious consumers, Sava is positioned to tap into the global wearables market projected to exceed $100 billion by 2029.
"With its world-first technology, breakthrough clinical trial results, and new funding, Sava is positioned to lead the next wave of innovation in the $100B+ global health wearables market," said Charlie Rubin, Investor at Pentland Ventures (search). "Beginning with CGM and creating a new market for real-time, multi-biomarker sensing."